DNTH
$78.90
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Recent News
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm
Dianthus Therapeutics (NASDAQ:DNTH) said it has made an “early go” decision to continue its CAPTIVATE Phase 3 trial evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), based on a planned interim responder analysis from Part A of the ongoing pivotal study. Management
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
Earlier this week, Dianthus Therapeutics completed an upsized follow-on offering raising about US$625.00 million in common stock and pre-funded warrants, shortly after reporting wider 2025 losses and lower revenue. At the same time, the company announced an early “go” decision in its Phase 3 CAPTIVATE trial of claseprubart in CIDP, suggesting the drug’s profile was strong enough to justify accelerating development plans and expanding its neuromuscular pipeline. We’ll now examine how the...
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The firm maintains its Buy rating on the stock with an upside potential of almost 207%. The adjustment follows […]
Dianthus Therapeutics Has Appreciated 12-Fold Over Two Years. What's Going On?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Top Midday Gainers
Relmada Therapeutics (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants